(Q35039495)

5 August 2017

1 reference

title

Trastuzumab use in breast cancer: clinical issues (English)

1 reference

5 August 2017

1 reference

John Horton

1

1 reference

5 August 2017

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

9

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

499-507

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Trastuzumab-associated cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Requirement for neuregulin receptor erbB2 in neural and cardiac development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: will it play in Peoria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Duration of therapy in metastatic breast cancer: management using Herceptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480200900607

10.1177/107327480200900607

21 January 2018

Identifiers

DOI

0 references

1 reference